Specialty Pharmacy

Novel therapeutic approach for multiple myeloma causes shows promising total cure rates.

Natalizumab linked to increased risk biomarkers for virus that can lead to potentially fatal condition.

Encapsulated human islet cells could improve maintenance of blood sugar levels in patients with diabetes.

RA patients who do yoga demonstrate benefits in health related quality of life measures.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

App can facilitate early detection and treatment of symptoms of chronic obstructive pulmonary disease.

Early detection is key in reducing the risk of heart failure in patients with cancer.

Testimony from public speakers at FDA advisory committee meetings under increased scrutiny.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

Nearly 15% of colorectal cancers diagnosed before the recommended screening age of 50.

Targeting enzyme found to slow progression of MS in human cells.

Cistus incanus found to inhibit viral proteins from infecting healthy cells.

Top news of the week in oncology drug development.

Higher risk of serious infection found with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.

Food additive induces cells to make protective antioxidants and make repairs.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Complications from conditions such as rheumatoid arthritis and lupus may cause cardiovascular problems.

Precision medicine and immune oncology transform cancer treatment.

Research explores how HIV is able to evolve during antiretroviral therapy.

Empliciti is an immunostimulatory antibody that targets the Signaling Lymphocyte Activation Molecule Family member 7.

Most read articles of the week on Specialty Pharmacy Times.

Optogenetics technique harnesses immune system to reduce tumor size and metastasis.

Predictors of poor medication adherence include increased regimen complexity, multiple comorbidities, and high medication cost.

Rapid intervention helps patient with hepatitis C avoid cirrhosis, carcinoma, and end-stage liver disease.

Study finds the greatest access to cost-sharing reduction subsidies translated to the lowest costs for patients with HIV.

Updated guidelines seek to decrease the risk of residual exposure to potentially dangerous medications.

CVS program indicates option of in-store pickup or home delivery improved adherence rates.

Treatment delivers miRNA to late-stage liver cancer tumors with low toxicity.